Buchang Pharmaceutical

Buchang Pharmaceutical is a Chinese pharmaceutical company associated primarily with traditional Chinese medicine products, especially treatments marketed for cardiovascular and cerebrovascular conditions. Its portfolio also includes chemical medicines, biopharmaceutical products, and other healthcare offerings. The company operates through research, manufacturing, distribution, and commercial promotion, with its principal business centered on the mainland Chinese market. The Buchang brand is particularly associated with products such as Naoxintong Capsules, Wenxin Granules, and Danhong Injection. These products occupy different positions within the Chinese medical-products market: Naoxintong is an oral traditional Chinese medicine used in the treatment of conditions related to blood stasis and cardiovascular or cerebrovascular disease; Wenxin Granules are used in the traditional Chinese medicine treatment of certain arrhythmia-related conditions; and Danhong Injection is an injectable traditional Chinese medicine product used in cardiovascular and cerebrovascular settings. Product indications, prescribing requirements, and clinical use depend on Chinese regulatory approvals and professional medical judgment. Buchang Pharmaceutical became a public company on the Shanghai Stock Exchange under the code 603858. Its public-company identity expanded the visibility of the Buchang name among Chinese pharmaceutical manufacturers and investors. The company’s commercial model reflects the structure of China’s prescription-drug market, in which hospital access, medical evidence, regulatory compliance, manufacturing quality, reimbursement policies, and procurement systems all influence product performance. The company’s positioning is rooted in the modernization and commercialization of traditional Chinese medicine. This includes developing standardized dosage forms, conducting clinical and pharmacological research, maintaining production facilities, and promoting products through medical and institutional channels. At the same time, its injectable and cardiovascular-focused products place the business in areas subject to heightened scrutiny regarding safety, evidence, rational use, adverse-event reporting, and public-health regulation. Buchang should be understood as a corporate pharmaceutical brand rather than as a single consumer remedy. Its identity is built around a portfolio of branded medicines and a broader research and manufacturing organization. Publicly available reference material in the supplied record does not establish a complete founding chronology, a verified current executive roster, or a fully documented international operating footprint; those details therefore remain unfilled here.

Buchang Pharmaceutical developed as a Chinese pharmaceutical business centered on branded traditional Chinese medicines and related healthcare products. The supplied reference material does not provide a sufficiently verified founding year or a complete account of the company’s early corporate development, so its initial chronology is left open rather than inferred. The company’s business identity is closely linked to the industrial production and commercialization of traditional Chinese medicines. In contrast with small-scale or purely retail traditional-remedy businesses, Buchang operates as a modern pharmaceutical manufacturer whose activities include product development, regulated production, distribution, and market access. Its portfolio has been associated particularly with cardiovascular and cerebrovascular treatment, a therapeutic area in which Chinese traditional medicines have been developed into capsules, granules, injections, and other standardized dosage forms. Products such as Naoxintong Capsules, Wenxin Granules, and Danhong Injection became important reference points for the Buchang name. Their presence across oral and injectable dosage forms illustrates the company’s participation in both traditional Chinese medicine and hospital-oriented prescription treatment. Their use is governed by approved indications, professional prescribing, safety monitoring, and changing Chinese healthcare policies. Buchang Pharmaceutical later became a listed company on the Shanghai Stock Exchange under ticker 603858. Listing increased the company’s public disclosure obligations and connected its corporate profile to China’s capital markets. It also placed the company’s operations within a policy environment shaped by pharmaceutical regulation, centralized or volume-based procurement, reimbursement reform, quality standards, clinical-evidence expectations, and oversight of traditional Chinese medicine products. In its contemporary form, Buchang is best characterized as a portfolio pharmaceutical company rather than a single-product brand. Its strategy combines established traditional Chinese medicine products with efforts involving chemical medicines, biological medicines, research, and manufacturing capabilities. The company’s principal commercial base is China. The supplied material does not substantiate a detailed global expansion history, verified executive succession record, or a complete list of subsidiaries and manufacturing sites, so those areas are not expanded here.

• 2016

  Shanghai Stock Exchange listing

  [2]Shanghai Stock Exchangesse.com.cn

  Buchang Pharmaceutical became publicly traded in Shanghai under stock code 603858, bringing the company under the disclosure and governance framework of a listed Chinese company.

• Corporate formation and development

  [1]Buchang Pharmaceutical official websitebuchang.com

  Buchang Pharmaceutical developed into a Chinese pharmaceutical manufacturer and brand portfolio company, but the supplied references do not establish a verified founding year.

A Chinese prescription-pharmaceutical company focused on traditional Chinese medicine and cardiovascular and cerebrovascular therapies, with additional chemical and biological medicine activities.

• Traditional Chinese medicine; cardiovascular and cerebrovascular medicine

  Naoxintong Capsules

  An oral traditional Chinese medicine product associated with the Buchang portfolio. It is marketed in China for approved cardiovascular and cerebrovascular indications involving traditional Chinese medicine concepts such as blood stasis. Its use, indication, dosage, and safety profile are governed by Chinese regulatory labeling and medical supervision.

• Traditional Chinese medicine; antiarrhythmic-related medicine

  Wenxin Granules

  A granulated traditional Chinese medicine product used in China in connection with certain arrhythmia-related conditions under approved indications. The product represents Buchang’s participation in standardized oral traditional Chinese medicine and hospital-oriented cardiovascular treatment.

• Traditional Chinese medicine injection; cardiovascular and cerebrovascular medicine

  Danhong Injection

  An injectable traditional Chinese medicine product associated with cardiovascular and cerebrovascular treatment in China. As an injectable prescription medicine, it is subject to professional administration, product labeling, adverse-event monitoring, and regulatory requirements applicable to Chinese pharmaceutical injections.

• 2019

  Chairman's family embroiled in U.S. college admissions fraud controversy

  In 2019, media reported that the family of Zhao Tao, chairman of Buchang Pharmaceuticals, paid US$6.5 million through an admissions intermediary, and his daughter was admitted to Stanford before her enrollment was revoked. Zhao Tao responded that the source of funds for studying abroad was unrelated to the listed company. This entry concerns a personal controversy involving the chairman's family; the cited reports did not find that Zhao Tao was criminally convicted or misappropriated company funds.

  Source

Read more

• 2016

  Public-market listingStrategy

  Background

  Buchang Pharmaceutical entered the public capital market as China’s pharmaceutical sector continued to develop under stronger disclosure, quality, reimbursement, and procurement requirements.

  Action taken

  The company listed on the Shanghai Stock Exchange under ticker 603858.

  Aftermath

  The listing made Buchang’s corporate and financial information subject to the reporting and governance requirements of a publicly traded company.

  Source

1. 1Buchang Pharmaceutical official websitebuchang.com
2. 2Shanghai Stock Exchangesse.com.cn
3. 3Chairman's family embroiled in U.S. college admissions fraud controversyeeo.com.cn